Low-dose azithromycin prophylaxis in patients with atrial fibrillation and chronic obstructive pulmonary disease

Tommaso Bucci,Dennis Wat,Sarah Sibley,Dan Wootton,David Green,Pasquale Pignatelli,Gregory Y. H. Lip,Freddy Frost

DOI: https://doi.org/10.1007/s11739-024-03653-0

2024-06-02

Internal and Emergency Medicine

Abstract:Low-dose azithromycin prophylaxis is associated with improved outcomes in people suffering frequent exacerbations of chronic obstructive pulmonary disease (COPD), but the use of macrolides in patients with cardiovascular disease has been debated. To investigate the risk of adverse events after COPD exacerbations in patients with atrial fibrillation (AF) treated with azithromycin prophylaxis. Retrospective cohort study within the TriNetX Platform, including AF patients with COPD exacerbations. Risks of primary and secondary outcomes were recorded up to 30 days post-COPD exacerbations and compared between azithromycin users and azithromycin non-users . The primary outcomes were the risks for a composite of (1) cardiovascular (all-cause death, heart failure, ventricular arrhythmias, ischemic stroke, myocardial infarction, and cardiac arrest), and (2) hemorrhagic events (intracranial hemorrhage (ICH), and gastro-intestinal bleeding). Cox-regression analyses compared outcomes between groups after propensity score matching (PSM). After PSM, azithromycin users ( n = 2434, 71 ± 10 years, 49% females) were associated with a lower 30-day risk of post-exacerbation cardiovascular (HR 0.67, 95% CI 0.61–0.73) and hemorrhagic composite outcome (HR 0.45, 95% CI 0.32–0.64) compared to azithromycin non-users ( n = 2434, 72 ± 11 years, 51% females) The beneficial effect was consistent for each secondary outcomes, except ICH. On sensitivity analyses, the reduced risk of adverse events in azithromycin users was irrespective of smoking status, exacerbation severity, and type of oral anticoagulation. Azithromycin prophylaxis is associated with a lower risk of all-cause death, thrombotic and hemorrhagic events in AF patients with COPD. The possible role of azithromycin prophylaxis as part of the integrated care management of AF patients with COPD needs further study.

medicine, general & internal

What problem does this paper attempt to address?

### Problems the Paper Aims to Address

This paper aims to explore whether low-dose azithromycin prophylactic treatment can reduce the risk of cardiovascular events and bleeding events within 30 days after acute exacerbation of chronic obstructive pulmonary disease (COPD) in patients with atrial fibrillation (AF). Specifically, the researchers hope to evaluate, through a retrospective cohort study, the difference in risk of cardiovascular events (including all-cause mortality, heart failure, ventricular arrhythmias, ischemic stroke, myocardial infarction, and cardiac arrest) and bleeding events (including intracranial hemorrhage and gastrointestinal bleeding) within 30 days after acute exacerbation of COPD between AF patients receiving low-dose azithromycin prophylactic treatment and those not receiving the treatment.

### Background and Motivation

1. **Relationship between COPD and Atrial Fibrillation**: COPD is one of the most common comorbidities in patients with atrial fibrillation, significantly increasing the risk of cardiovascular events and mortality.
2. **Risk of Acute Exacerbation of COPD**: Studies have shown that the risk of cardiovascular events is highest within the first 30 days after an acute exacerbation of COPD.
3. **Role of Azithromycin**: Low-dose oral azithromycin treatment is recommended by international guidelines for COPD patients with frequent acute exacerbations due to its anti-inflammatory effects, which can reduce the frequency of exacerbations.
4. **Controversy over Cardiovascular Safety**: Despite its anti-inflammatory effects, the cardiovascular safety of azithromycin remains controversial, especially regarding its potential to cause adverse cardiac reactions.

### Research Objectives

1. **Primary Objective**: To evaluate whether low-dose azithromycin prophylactic treatment can reduce the risk of composite cardiovascular events (including all-cause mortality, heart failure, ventricular arrhythmias, ischemic stroke, myocardial infarction, and cardiac arrest) and bleeding events (including intracranial hemorrhage and gastrointestinal bleeding) within 30 days after acute exacerbation of COPD in patients with atrial fibrillation.
2. **Secondary Objective**: To assess the risk of each individual cardiovascular event and bleeding event.

### Methods

1. **Study Design**: This is a retrospective cohort study based on the TriNetX platform, a global health research network covering approximately 80 million individuals' electronic medical records.
2. **Study Population**: Adult patients diagnosed with acute exacerbation of COPD were included. Azithromycin users were defined as those prescribed azithromycin for at least 3 months before the index event and still using it at the time of the index event. Non-users were defined as those with no history of azithromycin use in the 12 months before the index event.
3. **Matching Method**: Propensity score matching (PSM) 1:1 was used to control for differences between the comparison cohorts.
4. **Outcome Measures**: The primary outcome measures were the risk of composite cardiovascular events and bleeding events within 30 days after acute exacerbation of COPD. The secondary outcome measures were the risk of each individual cardiovascular event and bleeding event.

### Results

1. **Primary Results**: After PSM, azithromycin users (n=2434) had a lower risk of composite cardiovascular events (HR 0.67, 95% CI 0.61–0.73) and bleeding events (HR 0.45, 95% CI 0.32–0.64) within 30 days after acute exacerbation of COPD compared to non-users (n=2434).
2. **Secondary Results**: Azithromycin users also showed a lower risk for all individual cardiovascular events and bleeding events, except for intracranial hemorrhage.

### Discussion

1. **Main Findings**: Low-dose azithromycin prophylactic treatment significantly reduces the risk of all-cause mortality, cardiovascular events, and bleeding events within 30 days after acute exacerbation of COPD in patients with atrial fibrillation.
2. **Time Trend**: The risk reduction was most pronounced within the first week after acute exacerbation of COPD.
3. **Sensitivity Analysis**: The results remained consistent across multiple sensitivity analyses, including smokers, patients with severe acute exacerbation of COPD, and users of different types of oral anticoagulants.

### Conclusion

The data from this study suggest that long-term use of low-dose azithromycin prophylactic treatment can reduce the risk of cardiovascular events within 30 days after acute exacerbation of COPD in patients with atrial fibrillation. Further prospective studies are needed to validate these findings, understand the mechanisms, and identify the populations most likely to benefit.